Evidence map›Paper›PMID 33178779›Full record

ReviewAnnals of translational medicine2020

Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.

Shanthi Sabarimurugan, Arun Dharmarajan, Sudha Warrier, Maheswari Subramanian, Rajarajan Swaminathan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evaluation of in vitro activity of copper gluconate against SARS-CoV-2 using confocal microscopy-based high content screening.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shanthi SabarimuruganSchool of Biomedical Sciences, The University of Western Australia, Perth, Australia.
Arun DharmarajanCHIRI, School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA, Australia.
Sudha WarrierCHIRI, School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA, Australia.
Maheswari SubramanianDepartment of Microbiology, Centre for Research and PG Studies, Indian Academy of Degree College (Aut), Bangalore, India.
Rajarajan SwaminathanCentre for Drug Design, Discovery and Development, SRM University, Sonipat, Haryana, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent seemingly uncontrollable pandemic caused by the novel severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has been able to spread quickly due to the non-availability of effective antivirals or vaccines. The virus has structural and non-structural proteins that are considered as possible targets. Receptor recognition is the critical determinant and preliminary phase of viral infection to enter the host cell and causes tissue tropism. We have conducted a comprehensive review of relevant publication on

Indexed as

antiviralsCOVID-19repurposingSARS-CoV-1Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)

Identifiers

PMID33178779
PMCPMC7607133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.